Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | LPO | P22079 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14790242 | 0.80 | L3MBTL1 (0.39) | NUDT1L3MBTL1TNKS | |
| SCHEMBL15687846 | 0.75 | L3MBTL1 (0.47) | NUDT1L3MBTL1TNKSADORA2A | |
| SCHEMBL21863368 | 0.75 | L3MBTL1 (0.43) | NUDT1L3MBTL1TNKS | |
| SCHEMBL15066625 | 0.73 | L3MBTL1 (0.34) | NUDT1L3MBTL1 | |
| SCHEMBL5408540 | 0.73 | NUDT1 (0.46) | NUDT1L3MBTL1 | |
| SCHEMBL19520117 | 0.73 | NUDT1 (0.46) | NUDT1L3MBTL1TNKS | |
| SCHEMBL19630404 | 0.72 | NUDT1 (0.45) | NUDT1L3MBTL1TNKSDYRK1AADORA2A | |
| SCHEMBL12778120 | 0.72 | L3MBTL1 (0.41) | NUDT1L3MBTL1TNKS | |
| SCHEMBL19865160 | 0.72 | L3MBTL1 (0.53) | NUDT1L3MBTL1TNKSADORA2A | |
| SCHEMBL17974717 | 0.72 | L3MBTL1 (0.40) | NUDT1L3MBTL1TNKSPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024092069-A1 | CXCR4 INHIBITORS FOR TREATMENT OF NEUROLOGICAL DISEASES | X4 PHARMACEUTICALS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023196601-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-29 | — | — | US | disclosed |
| WO-2023102184-A1 | BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| WO-2021263203-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| EP-3845526-A1 | METHOD FOR THE PREPARATION OF TETRAHYDROQUINOLINONE COMPOUNDS HAVING ROR-GAMMA MODULATING ACTIVITY | Aurigene Discovery Technologies Limited (IN) | 2021-07-07 | — | — | EP | disclosed |
| US-10988465-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| WO-2021076688-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-8530652-B2 | Pyrrolopyrazoles, potent kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530652-B2 | Pyrrolopyrazoles, potent kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20120264751-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2012-10-18 | — | — | US | disclosed |
| US-20120264751-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2012-10-18 | — | — | US | disclosed |
| US-20120132899-A1 | NITROGENATED HETEROCYCLIC RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120132899-A1 | NITROGENATED HETEROCYCLIC RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| WO-2011036885-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2011-03-31 | — | — | WO | disclosed |
| US-7709468-B2 | Imidazo based heterocycles | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | disclosed |
| US-20070099925-A1 | Novel imidazo based heterocycles | ABBVIE INC. | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | NUDT1 3852/4885L3MBTL1 2746/4885TNKS 492/4885 |
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | CDK12, CDK1, CDK2 | NUDT1 1574/4885L3MBTL1 3125/4885TNKS 252/4885 |
| US-20070099925-A1 | Novel imidazo based heterocycles | CDK4, CDK2, MAP3K19 | NUDT1 1635/4885L3MBTL1 4133/4885TNKS 584/4885 |
| US-20120132899-A1 | NITROGENATED HETEROCYCLIC RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | H1-2, L1CAM, H1-0 | NUDT1 1543/4885L3MBTL1 758/4885TNKS 3860/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | NUDT1 4847/4885L3MBTL1 721/4885TNKS 3262/4885 |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | NFATC1, AADAT, ACAT1 | NUDT1 8/4885L3MBTL1 4008/4885TNKS 1276/4885 |
| US-20120264751-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PAK4, PAK5, PAK3 | NUDT1 2241/4885L3MBTL1 4137/4885TNKS 646/4885 |
| US-10988465-B2 | CXCR4 inhibitors and uses thereof | CXCR4, CXCL12, CXCR3 | NUDT1 1137/4885L3MBTL1 3322/4885TNKS 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.